Evidence map›Paper›PMID 27995906›Full record

GuidelineThe American journal of gastroenterology2017

ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries.

Paul Y Kwo, Stanley M Cohen, Joseph K Lim

Abstract readPractice Guideline
PubMed Publisher
In one paragraph

Guideline in The American journal of gastroenterology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 561 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
561citing papers in PubMed, 8 pooled it
38.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

561 citing papers in PubMed, 8 syntheses or guidelines pooled it, 1,134 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pharmacological Mechanisms of Bile Acids Targeting the Farnesoid X Receptor.International journal of molecular sciences · 2024
    Pooled it
  6. Pooled it
  7. Guideline
  8. Pooled it
  9. Trial
  10. Trial
  11. Effect of Normothermic Machine Perfusion on Glycocalyx Shedding During Liver Transplantation - A Prospective Pilot Study.Transplant international : official journal of the European Society for Organ Transplantation · 2026
    Trial
  12. Trial
  13. Serum Transaminases and Older Adults: Distribution and Associations With All-Cause Mortality.The journals of gerontology. Series A, Biological sciences and medical sciences · 2024
    Trial
  14. Trial
  15. Trial
  16. Article
  17. pgRNA-mEpigenetics · 2026
    Article
  18. Article
  19. Review
  20. Article

501 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Paul Y KwoDivision of Gastroenterology/Hepatology, Department of Medicine, Stanford University School of Medicine, Palo Alto, California, USA.
Stanley M CohenDigestive Health Institute, University Hospitals Cleveland Medical Center and Division of Gastroenterology and Liver Disease, Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
Joseph K LimYale Viral Hepatitis Program, Yale University School of Medicine, New Haven, Connecticut, USA.
Stanford University · USUniversity Hospitals of Cleveland · USYale University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clinicians are required to assess abnormal liver chemistries on a daily basis. The most common liver chemistries ordered are serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase and bilirubin. These tests should be termed liver chemistries or liver tests. Hepatocellular injury is defined as disproportionate elevation of AST and ALT levels compared with alkaline phosphatase levels. Cholestatic injury is defined as disproportionate elevation of alkaline phosphatase level as compared with AST and ALT levels. The majority of bilirubin circulates as unconjugated bilirubin and an elevated conjugated bilirubin implies hepatocellular disease or cholestasis. Multiple studies have demonstrated that the presence of an elevated ALT has been associated with increased liver-related mortality. A true healthy normal ALT level ranges from 29 to 33 IU/l for males, 19 to 25 IU/l for females and levels above this should be assessed. The degree of elevation of ALT and or AST in the clinical setting helps guide the evaluation. The evaluation of hepatocellular injury includes testing for viral hepatitis A, B, and C, assessment for nonalcoholic fatty liver disease and alcoholic liver disease, screening for hereditary hemochromatosis, autoimmune hepatitis, Wilson's disease, and alpha-1 antitrypsin deficiency. In addition, a history of prescribed and over-the-counter medicines should be sought. For the evaluation of an alkaline phosphatase elevation determined to be of hepatic origin, testing for primary biliary cholangitis and primary sclerosing cholangitis should be undertaken. Total bilirubin elevation can occur in either cholestatic or hepatocellular diseases. Elevated total serum bilirubin levels should be fractionated to direct and indirect bilirubin fractions and an elevated serum conjugated bilirubin implies hepatocellular disease or biliary obstruction in most settings. A liver biopsy may be considered when serologic testing and imaging fails to elucidate a diagnosis, to stage a condition, or when multiple diagnoses are possible.

Indexed as

Alanine TransaminaseAlkaline Phosphatasealpha 1-Antitrypsin DeficiencyAspartate AminotransferasesBilirubinBiopsyChemical and Drug Induced Liver InjuryCholestasisHemochromatosisHepatitis, AutoimmuneHepatitis, Viral, HumanHepatolenticular DegenerationHumansLiverLiver DiseasesLiver Diseases, AlcoholicAlanine TransaminaseAlkaline PhosphataseAspartate AminotransferasesBilirubin

Identifiers

PMID27995906
OpenAlexW2563118732

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.